NNC0519-0130 vs olatorepatide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline
NNC0519-0130
Developed by Novo Nordisk
NCT06326060 · Phase 2 · completed
The study was randomized and quadruple-blind, included placebo and active-comparator arms, and enrolled 354 participants; its primary endpoint was the clinical measure of relative body-weight change. Because the registry does not report whether this endpoint was met, the findings cannot currently support the highest evidence grade.
No aligned efficacy figure on record for this race.
olatorepatide
Developed by Regeneron Pharmaceuticals under a licence from Hansoh Pharmaceutical Group
NCT06839664 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2028 · NCT07685808 (registry estimate)
Reported efficacy
Percent Change from Baseline in Body Weight (Baseline, week 48); Percentage of Participants Who Achieve weight loss≥ 5% from Baseline (Baseline, week 48): Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. (met)
Result source: NCT06839664
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | NNC0519-0130 | olatorepatide |
|---|---|---|
| Body weight, % change | —Not reported | —Not posted · NCT06839664 |
| Weight loss of 5% or more | —Not reported | —Not posted · NCT06839664 |
| Weight loss of 10% or more | —Not reported | —Not posted · NCT06839664 |
| Waist circumference, change (cm) | —Not reported | —Not posted · NCT06839664 |
Body weight, % change
- NNC0519-0130
- —Not reported
- olatorepatide
- —Not posted · NCT06839664
Weight loss of 5% or more
- NNC0519-0130
- —Not reported
- olatorepatide
- —Not posted · NCT06839664
Weight loss of 10% or more
- NNC0519-0130
- —Not reported
- olatorepatide
- —Not posted · NCT06839664
Waist circumference, change (cm)
- NNC0519-0130
- —Not reported
- olatorepatide
- —Not posted · NCT06839664
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NNC0519-0130: no structured comparison results are available for Obesity.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
olatorepatide
Type 2 Diabetes
Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline
NNC0519-0130
Developed by Novo Nordisk
NCT05363774 · Phase 1 · completed
This was a randomized, blinded, placebo-controlled study, a genuine controlled design, but it measured only safety and drug levels rather than a clinical efficacy outcome, and results have not been posted yet, so the evidence reflects the design only. Its registered primary outcome on ClinicalTrials.gov is "Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
olatorepatide
Developed by Regeneron Pharmaceuticals under a licence from Hansoh Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07156500 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | NNC0519-0130 | olatorepatide |
|---|---|---|
| HbA1c, change | —Not reported | —Trial running · NCT07156500 |
| Body weight, change (kg) | —Not reported | —Trial running · NCT07156500 |
| HbA1c below 7% | —Not reported | —Trial running · NCT07156500 |
| Fasting plasma glucose, change | —Not reported | —Trial running · NCT07156500 |
| 3-point MACE (% with event) | —Not reported | —Trial running · NCT07156500 |
HbA1c, change
- NNC0519-0130
- —Not reported
- olatorepatide
- —Trial running · NCT07156500
Body weight, change (kg)
- NNC0519-0130
- —Not reported
- olatorepatide
- —Trial running · NCT07156500
HbA1c below 7%
- NNC0519-0130
- —Not reported
- olatorepatide
- —Trial running · NCT07156500
Fasting plasma glucose, change
- NNC0519-0130
- —Not reported
- olatorepatide
- —Trial running · NCT07156500
3-point MACE (% with event)
- NNC0519-0130
- —Not reported
- olatorepatide
- —Trial running · NCT07156500
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NNC0519-0130: no structured comparison results are available for Type 2 Diabetes.
olatorepatide: no structured comparison results are available for Type 2 Diabetes.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNC0519-0130's landscape · olatorepatide's landscape